Literature DB >> 21576823

Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.

Edward M Behrens1, Scott W Canna, Katharine Slade, Sheila Rao, Portia A Kreiger, Michele Paessler, Taku Kambayashi, Gary A Koretzky.   

Abstract

Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are 2 similar diseases characterized by a cytokine storm, overwhelming inflammation, multiorgan dysfunction, and death. Animal models of HLH suggest that disease is driven by IFN-γ produced by CD8⁺ lymphocytes stimulated by persistent antigen exposure. In these models and patients with "primary" HLH, the antigen persists due to genetic defects, resulting in ineffective cytotoxic responses by CD8⁺ T cells and poor pathogen clearance. However, infectious triggers are often not identified in patients with MAS, and some patients with HLH or MAS lack defects in cytotoxic T cell killing. Herein, we show that repeated stimulation of TLR9 produced an HLH/MAS-like syndrome on a normal genetic background, without exogenous antigen. Like previous HLH models, TLR9-induced MAS was IFN-γ dependent; however, unlike other models, disease did not require lymphocytes. We further showed that IL-10 played a protective role in this model and that blocking IL-10 signaling led to the development of hemophagocytosis. IL-10 may therefore be an important target for the development of effective therapeutics for MAS. Our data provide insight into MAS-like syndromes in patients with inflammatory diseases in which there is chronic innate immune activation but no genetic defects in cytotoxic cell function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576823      PMCID: PMC3104738          DOI: 10.1172/JCI43157

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor.

Authors:  B François; F Trimoreau; P Vignon; P Fixe; V Praloran; H Gastinne
Journal:  Am J Med       Date:  1997-08       Impact factor: 4.965

2.  Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus.

Authors:  Sean R Christensen; Jonathan Shupe; Kevin Nickerson; Michael Kashgarian; Richard A Flavell; Mark J Shlomchik
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

3.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

4.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

5.  Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus.

Authors:  Aurelia Lartigue; Philippe Courville; Isabelle Auquit; Arnaud François; Christophe Arnoult; François Tron; Daniele Gilbert; Philippe Musette
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

6.  The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.

Authors:  Jack Bleesing; Anne Prada; David M Siegel; Joyce Villanueva; Judyann Olson; Norman T Ilowite; Hermine I Brunner; Thomas Griffin; Thomas B Graham; David D Sherry; Murray H Passo; Athimalaipet V Ramanan; Alexandra Filipovich; Alexei A Grom
Journal:  Arthritis Rheum       Date:  2007-03

7.  Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin.

Authors:  Christian A Schaer; Gabriele Schoedon; Alexander Imhof; Michael O Kurrer; Dominik J Schaer
Journal:  Circ Res       Date:  2006-09-28       Impact factor: 17.367

8.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

9.  CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion.

Authors:  Miguel A Sanjuan; Navin Rao; Kuei-Tai A Lai; Yin Gu; Siquan Sun; Anja Fuchs; Wai-Ping Fung-Leung; Marco Colonna; Lars Karlsson
Journal:  J Cell Biol       Date:  2006-03-27       Impact factor: 10.539

10.  Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis.

Authors:  Karine Crozat; Kasper Hoebe; Sophie Ugolini; Nancy A Hong; Edith Janssen; Sophie Rutschmann; Suzanne Mudd; Sosathya Sovath; Eric Vivier; Bruce Beutler
Journal:  J Exp Med       Date:  2007-04-09       Impact factor: 14.307

View more
  132 in total

1.  Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation.

Authors:  Maria L Mouchess; Nicholas Arpaia; Gianne Souza; Roman Barbalat; Sarah E Ewald; Laura Lau; Gregory M Barton
Journal:  Immunity       Date:  2011-11-10       Impact factor: 31.745

2.  Line-selective macrophage activation with an anti-CD40 antibody drives a hemophagocytic syndrome in mice.

Authors:  Giada Ingoglia; Ayla Yalamanoglu; Marc Pfefferlé; Irina L Dubach; Christian A Schaer; Kristyna Valkova; Kerstin Hansen; Nadja Schulthess; Rok Humar; Dominik J Schaer; Florence Vallelian
Journal:  Blood Adv       Date:  2020-06-23

3.  Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect.

Authors:  Julien Carvelli; Christelle Piperoglou; Catherine Farnarier; Frédéric Vely; Karin Mazodier; Sandra Audonnet; Patrick Nitschke; Christine Bole-Feysot; Mohamed Boucekine; Audrey Cambon; Mohamed Hamidou; Jean-Robert Harle; Geneviève de Saint Basile; Gilles Kaplanski
Journal:  Blood       Date:  2020-07-30       Impact factor: 22.113

4.  Dysregulation of TLR9 in neonates leads to fatal inflammatory disease driven by IFN-γ.

Authors:  Alison G Stanbery; Zachary R Newman; Gregory M Barton
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-24       Impact factor: 11.205

5.  Increased ribonuclease expression reduces inflammation and prolongs survival in TLR7 transgenic mice.

Authors:  Xizhang Sun; Alice Wiedeman; Nalini Agrawal; Thomas H Teal; Lena Tanaka; Kelly L Hudkins; Charles E Alpers; Silvia Bolland; Matthew B Buechler; Jessica A Hamerman; Jeffrey A Ledbetter; Denny Liggitt; Keith B Elkon
Journal:  J Immunol       Date:  2013-02-04       Impact factor: 5.422

6.  Brief Report: Interferon-γ-Mediated Immunopathology Potentiated by Toll-Like Receptor 9 Activation in a Murine Model of Macrophage Activation Syndrome.

Authors:  Lehn K Weaver; Niansheng Chu; Edward M Behrens
Journal:  Arthritis Rheumatol       Date:  2018-11-24       Impact factor: 10.995

7.  A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.

Authors:  Mark Wunderlich; Courtney Stockman; Mahima Devarajan; Navin Ravishankar; Christina Sexton; Ashish R Kumar; Benjamin Mizukawa; James C Mulloy
Journal:  JCI Insight       Date:  2016-09-22

8.  Understanding Disseminated Intravascular Coagulation and Hepatobiliary Dysfunction Multiple Organ Failure in Hyperferritinemic Critical Illness.

Authors:  Joseph A Carcillo; Bita Shakoory; Dennis Simon; Kate Kernan
Journal:  Pediatr Crit Care Med       Date:  2018-10       Impact factor: 3.624

9.  TLR9-mediated inflammation drives a Ccr2-independent peripheral monocytosis through enhanced extramedullary monocytopoiesis.

Authors:  Lehn K Weaver; Niansheng Chu; Edward M Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-12       Impact factor: 11.205

10.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.